RecruitingPhase 2NCT07171606
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Enrollment
240 participants
Start Date
Oct 24, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- Males and/or females over age 18
- Histologically and/or cytologically documented local advanced or metastatic NSCLC .
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Expected survival \>=3 months.
- Signed informed consent form.
Exclusion Criteria6
- Known uncontrolled or symptomatic central nervous system metastatic disease.
- Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
- Inadequate organ or bone marrow function.
- Pregnant or breast-feeding woman.
- Known allergies, hypersensitivity, or intolerance to SSGJ-706
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Interventions
DRUGSSGJ-706
PD-1/PD-L1 bispecific antibody
DRUGpemetrexed /carboplatin
chemotherapy
DRUGCarboplatin/Paclitaxel
chemotherapy
DRUGPD-1 Inhibitor + Chemotherapy
control group
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07171606